WTO Price Transparency Talks Face Resistance From Developed Countries
Last week the World Trade Organization’s TRIPS Council discussed transparency in medicine pricing, including R&D costs.
You may also be interested in...
The World Trade Organization is not the place to discuss pharmaceutical pricing, and strong intellectual property rights do not threaten access to medicines, according to EU and US delegations to the WTO.
Following on from moves to push price transparency on to the global agenda, Italy is poised to pass a decree that would oblige companies to disclose public R&D funding.
EU countries should use a milestone World Health Organization resolution calling for more transparency on net medicine prices to help secure better access to medicine, says the Valletta group.